SEC Filing Summary: PharmAthene, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by PharmAthene, Inc. on September 10, 2012. The filing serves to disclose a presentation scheduled for the Rodman & Renshaw Annual Global Investment Conference on the same date. The registrant is incorporated in Delaware and maintains its principal executive offices in Annapolis, Maryland.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing to attach a presentation and does not contain audited financial statements or quarterly results.
Material Changes
No material changes to financial performance or operations are reported within the text of this filing. The primary event is the dissemination of investor presentation materials.
Guidance, Outlook, and Risks
The filing references an attached presentation (Exhibit 99.1) containing management commentary and outlook, but the content of that presentation is not included in the text provided. The filing explicitly states that the information, including the attached exhibit, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section. Consequently, no specific risks, contingencies, or unusual items are detailed in this report text.
Key Facts for Investor Verification
- Verify the content of the attached Exhibit 99.1 (PharmAthene Presentation) for actual business updates, as the 8-K text only references it.
- Note that the presentation materials are not incorporated by reference into other SEC filings unless expressly stated.
- Confirm the company's current status, as the filing metadata in the prompt mentions "Altimmune, Inc." while the document text clearly identifies the registrant as PharmAthene, Inc.